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Abstract
tions (ADRs) has the potential to reduce the personal and population costs of drug-related morbidity. Some individuals may show an increased susceptibility to certain ADRs through genetic polymorphisms that alter their responses to various drugs.
We wished to establish a methodology that would be acceptable to members of the general population and that would enable estimation of the risks that specific genetic factors confer on susceptibility to specific ADRs. Buccal swabs were selected as a minimally invasive method to obtain cells for DNA extraction. We wished to determine whether DNA of sufficient quantity and quality could be obtained to enable genotyping for two different polymorphic genes that code for enzymes that are widely involved in drug disposition.
This article describes a small pilot study of methodology developed in the New Zealand Intensive Medicines Monitoring Programme (IMMP) to link prescription event monitoring (PEM) studies with pharmacogenetics. The methodology involves a nested case-control study design to investigate whether patients with genetic variants in P-glycoprotein (P-gp) and cytochrome P450 (CYP) 2C9 are more susceptible to psychiatric or visual disturbances following cyclooxygenase-2 inhibitor use (ADR signals identified in the IMMP database) than matched control patients taking the medication without experiencing any ADRs.
It was concluded that the use of buccal swabs is acceptable to patients and provides DNA of sufficient quantity and quality for genotyping. Although no differences in the distribution of genotypes in the case and control populations were found in this small study, case-control studies investigating genetic risks for ADRs using drug cohorts from PEM studies are possible, and there are several areas where population-based studies of genetic risk factors for ADRs are needed.
Examples are discussed where research in large populations is required urgently. These are: (i) genetic variations affecting P-gp function; (ii) variations affecting drugs metabolised by CYP2C9 and other polymorphic CYP enzymes; (iii) genetic variation in β-adrenergic receptors and adverse outcomes from β-adrenoceptor agonist therapy; and (iv) genetic variation in cardiac cell membrane potassium channels and their association with long QT syndromes and serious cardiac dysrhythmias.
Such studies will help to identify factors that increase the risk of unwanted outcomes from drug therapy. They will also help to establish in what circumstances genotyping should be performed prior to commencing drug treatment and in tailoring drug treatment for individual patients.
The ability to identify individuals who are sus-
The New Zealand Intensive Medicines ceptible to adverse drug reactions (ADRs) has the
Monitoring Programme potential to reduce the personal and population costs of drug-related morbidity. Genetic polymorphisms
The New Zealand IMMP began in 1977 [1] and may alter the pharmacokinetics or pharmacodynam-was designed to play a significant part in monitoring ics of a given drug in ways that affect the response to for previously unrecognised ADRs.
[2] Generally, the drug concerned and create an increased suscepti-medicines are selected for inclusion in the IMMP if bility to certain ADRs. they are of a new class and are likely to be used This article is based on a presentation made as widely. A near complete record is obtained of all part of a symposium on 'Risk Factors in Pharmaco-patients who have been prescribed these medicines genetics' during the Annual Scientific Meeting of by recording all prescriptions dispensed throughout the International Society of Pharmacovigilance the whole monitoring period. Monitoring is usually (ISoP) held in Marrakesh, Morocco in October continued for 4-5 years, which is sufficient time to 2003. The paper describes the methodology devel-accumulate a cohort of adequate size for epidemiooped in the New Zealand Intensive Medicines Moni-logical investigations. The methodology utilises the toring Programme (IMMP) aimed at linking technique now known as PEM. A similar methodolpharmacoepidemiology with pharmacogenetics in ogy is used by the DSRU in England.
[3] In the order to estimate the degree to which specific genet-IMMP, prescription records for the monitored ic factors alter susceptibility to some ADRs, and the medicines are received from dispensing pharmacists results from a small pilot study are given. Future in community and hospital pharmacies throughout directions are discussed and examples considered of the country. The details recorded in each drug cohort important areas where genetic studies in prescrip-includes prescribers' names and addresses; the tion event monitoring (PEM) cohorts are opportune names, addresses, dates of birth and sex of patients and are underway using the IMMP cohorts and the who have been prescribed the medicines; details of cohorts from the Drug Safety Research Unit each prescription (medicine, dose, date and quantity (DSRU) in England. dispensed) and indication for treatment.
Adverse events are defined as any untoward ex-er, to date, most investigations have focused on perience whether or not the event is thought to be variability in single genes predicted to contribute to drug related.
[4] These events include changes in a inter-individual differences in drug responses (i.e. pre-existing condition or abnormally changed labo-pharmacogenetics). ratory values and all deaths. The method is based on Several pharmacogenetic studies have provided sending questionnaires to the prescribers at regular evidence that in specific populations some subjects intervals following receipt and data entry of new have particular single nucleotide polymorphisms prescription details. Doctors are requested to record (SNPs) or a set of closely linked SNPs on a chromoall events noted in the patient records from the time some (haplotypes) that influence their response to of commencement of the drug or the latest prescripspecific drugs. [6] [7] [8] [9] [10] [11] [12] It is thus important to identify tion, whichever is appropriate. These forms are whether specific SNPs or haplotypes may lead to computer generated and include all prescribing and clinically important differences in drug response patient details and the first and most recent dispensing dates for reference. Doctors may also record and ADRs. We have previously demonstrated that events on IMMP duplicate prescriptions or send pharmacogenetic studies are feasible in patients respontaneous reports on the standard 'yellow' card.
ported with adverse reactions. [13] However, because Because the IMMP databases include records of these earlier studies required physicians to collect monitored medicines over a known time period, blood samples for DNA extraction, the number of including those from patients who have not exper-patients willing to participate, and so subject themienced an adverse event, the incidence of events can selves to an invasive sampling procedure, was small. be calculated. The details of age, sex, dose, treat-In the pilot investigation described in this article, we ment duration and indication for treatment allow the wished to assess whether buccal cell samples could identification of risk factors using cases and controls yield enough DNA of sufficient quality for genotypfrom the individual cohorts. The study of risk factors ing in larger population studies. can include genetic variation that may increase susAs part of the normal monitoring of rofecoxib ceptibility to the adverse event.
and celecoxib (cyclo-oxygenase [COX]-2 inhibitors), the New Zealand IMMP has received a num-2. Investigations into Genetic Factors ber of reports of visual [14] and psychiatric [15] disturAffecting Drug Response bances that appear after COX-2 inhibitor use and resolve following withdrawal. [14] The strong eviThe field of research that uses large-scale, sys-dence of causality from these reports and details of tematic genomic approaches to identify multiple the types of visual and psychiatric disturbances asdrug response marker genes is known as sociated with COX-2 inhibitor use have been pubpharmacogenomics. It is likely that this approach lished. [14, 15] We hypothesised that there may be idenwill be increasingly used to identify genetic factors tifiable genetic factors that increased the risk of such that may influence an individual's response to a events in these patients. The pilot study was thereparticular drug and thus assist in determining the fore designed to investigate whether selected genetoptimum drug regimen for that individual.
ic polymorphisms contribute to the risk of developPharmacogenomic approaches are also increasingly ing visual or psychiatric disturbances following the being used by the drug industry to predict potential use of rofecoxib or celecoxib. problem areas during drug development. [5] Howev-
The Pilot Study
The pilot case-control study was designed, involving patients from the IMMP who were currently This study investigated the potential role of ge-taking rofecoxib or celecoxib, to test the hypothesis netic polymorphisms in P-glycoprotein (P-gp) and that variant forms of P-gp and/or CYP2C9 are assocytochrome P450 (CYP) 2C9 in the visual and psy-ciated with the rare visual or psychiatric disturchiatric disturbances experienced by some patients bances reported. Patients were genotyped for selectprescribed COX-2 inhibitors.
ed SNPs in the genes encoding P-gp (ABCB1) and National ethical approval was given for the use of CYP2C9 (CYP2C9). Previous experience using the IMMP data in this study and for the sampling DNA extracted from blood samples yielded a very and genotyping of patients.
low number of patients willing to participate. [13] Therefore, it was considered essential for a study of 3.1 Rationale this nature that another method of DNA collection was adopted, and a simple buccal swab sampling For most drug-related visual distubances and for method was selected. psychiatric disturbances to occur, the drug con-
The primary aims of the pilot study were: (i) to cerned must cross the blood-brain barrier. Several determine whether pharmacogenetic studies using a variants of the transporter protein P-gp show re-minimally invasive method of obtaining DNA are duced ability to extrude drugs and other substrates feasible, using a PEM database as a method of from cells. [12, 16] It is not yet known whether COX-2 recruiting cohorts of patients exposed to the same inhibitors are substrates for P-gp, but if this is the drug, both with and without specific reactions; and case, the presence of variant P-gp forms may lead to (ii) to determine whether a buccal swab sampling an increase in drug absorption or movement across method would enable the collection of sufficient the blood-brain barrier with resulting high plasma or cells from inside the cheek for the extraction of brain concentrations; should the distribution of poor DNA and subsequent ABCB1 and CYP2C9 genotyp-P-gp transport efflux genotypes be greater in these ing. cases, this would highlight the need for in vitro studies to confirm whether the COX-2 inhibitors are 3.2 Methodology substrates for P-gp. As prostacyclin plays an important role in the control of retinal blood flow [17] and
Recruitment of Patients

COX-2 inhibitors reduce prostacyclin synthesis in
Subjects experiencing psychiatric or visual disthe vascular endothelium, [18] an altered transport of turbances with celecoxib or rofecoxib that were of celecoxib or rofecoxib may contribute to the visual similar type to those previously reported by the or psychiatric disturbances. IMMP [14, 15] were selected from the IMMP event Patients experiencing the events may have inher-databases. Patients who were not experiencing any ited a gene that codes for variant CYP2C9 enzymes adverse events were selected from the IMMP cothat have been demonstrated to have a reduced abili-horts as controls. Prescribers were asked to indicate ty to metabolise certain drugs, including celecox-whether patients (cases and controls) were taking ib [19] and some other NSAIDs. [20, 21] Therefore, it is specific listed medications (amiodarone, fluconapossible that genetic variability in proteins involved zole, paroxetine, probenecid, sertraline, trimethoin the uptake or metabolism of COX-2 inhibitors prim and cotrimoxazole [trimethoprim/sulmay contribute to an increased risk of developing famethoxazole]) that might possibly interact with Pvisual and/or psychiatric disturbances.
gp or CYP2C9 substrates. None of the patients were taking these medications during the times that results were sent to Dunedin, New Zealand, for celecoxib or rofecoxib was prescribed. interpretation and analysis in collaboration with the laboratory in Christchurch, New Zealand. The control patients were matched by date of birth (within 5 years), sex and geographical location.
Genotyping of Samples
Where possible, two control patients who were preGenotyping for selected CYP2C9 (*1,*2 and *3) scribed the same COX-2 inhibitor by the same docand ABCB1 (3435C>T) variants was performed ustor were matched for each case. For each case, we ing methods already established within the Christprovided the patient's doctor with the identification church laboratory. [22, 23] The method of buccal cell of three possible controls from the IMMP cohorts sampling allows the recovery of sufficient cells from and requested that he/she select the two most approwhich to isolate DNA. The DNA was extracted priate. If the doctor could not identify any suitable using the method described by Richards et al., [24] controls, we sought controls from other doctors locoded by number and date and stored at -20ºC until cated in the same practice or general area. As some analysed. patients had died and others were considered too frail or ill to participate, a total of 37 cases and 91
Analysis of Results
controls were selected and invited to enrol.
Differences in the frequency of variants between cases and controls and between cases taking
Obtaining the Buccal Cell Samples
celecoxib and rofecoxib were tested using relative General practitioners (GPs) were identified from risks with confidence intervals. Chi-squared tests the IMMP database and contacted by mail with an were also applied. explanation of the purpose of the investigation and were asked for approval to approach their patient(s). Once the GP's approval had been obtained, patients (37 cases and 91 controls) were contacted by mail with an explanation of the study, invited to participate and asked to provide consent for their participation. The patients were informed that participation would be at no cost to them and would involve making an appointment with their doctor so that a swab could be taken from inside their cheek to obtain a cell sample for DNA extraction.
Once informed consent had been received from the patients (consent was received from 17 cases and 31 controls), the GPs were asked to return additional details of the reported event, concurrent medications and conditions. They were then sent kits for the collection of buccal cell samples (figure 1). These were coded prior to being sent to the GPs so that the subsequent genotyping was blind. The GPs were requested to post the samples, using the reply paid courier packs provided in the kit, to the genetics laboratory for DNA extraction and genotyping. The might be prescribed in the future, they should contact their GP. In addition to the letters containing their individual patients' results, the GPs were also sent a document with an explanation and list of other medicines that might be affected by the genetic variants of CYP2C9 and P-gp that were identified for their patients.
Results
Of the 37 case and 91 control patients who were approached to participate in the study, genotyping was carried out on 15 case and 24 control patients. Consent forms from the remaining nine patients were received too late for the genotypes to be included in this study. The DNA obtained from buccal cells was of sufficient quality in all samples tested to enable ABCB1 and CYP2C9 genotyping (figure 2). In the small sample size genotyped, the distributions of variant genotypes were similar between cases and controls and across drugs (table I).
Discussion
Genetic polymorphisms may contribute to interindividual differences in drug response by altering pharmacokinetics (e.g. where drug blood concentrations may be affected by variation in drugmetabolising enzymes or in transport proteins involved in drug uptake) or by altering pharmacodynamics (e.g. where variation in receptors, ion channels or intracellular enzymes or in other cell/tissue components may lead to altered drug response).
There are several studies that indicate that Similarly, DNA samples were screened for the CYP2C9*2 (representative gel not shown) and CYP2C9*3 alleles using PCR followed by digestion of the PCR products with different restriction endonucleases. Lanes 1, 3 and 6 are heterozygous for CYP2C9*3; and lanes 2, 4, 5 and 7 are homozygotes for the wildtype (CYP2C9*1) allele. No CYP2C9*3 homozygotes were found in the pilot study. The PCR fragments for both assays were separated on 3% agarose and sized using a 25bp DNA ladder (M).
polymorphisms in genes coding for proteins involved in pharmacokinetic and pharmacodynamic
Feedback to Patients and
processes influence the effects of administered
General Practitioners
drugs, thereby altering susceptibility to ADRs. Letters were sent to the GPs and patients inform-However, most of these studies have compared ing them of the individual results. Patient letters small, selected samples of the population, such as included a recommendation that if the patients those with or without particular variant genes (e.g. wished to discuss the wider implication of their studies comparing 'extensive metaboliser' with results with respect to other medicines that they 'poor metaboliser' populations) and using short- a Control genotypes 1 and 2 indicate matched controls. A further five controls were genotyped that had been matched to cases that did not consent to genotyping. The genotypes of these control patients were: C/C *1*1; C/T *1*1; CT/*1*2; TT/*1*1; and TT/*1*3. In only four cases were two matched controls per case able to be obtained for genotyping. Allelic variants that may lead to altered plasma or CNS levels of substrates are shown in bold.
term dosage regimens. [25] Therefore, it should be In order to test the feasibility of such a population helpful to use epidemiological methods to estimate study, where the minimally invasive method of usthe risk of increased susceptibility to ADRs due to ing buccal swabs was used for obtaining DNA for pharmacogenetic factors, where comparisons are genotyping, we conducted a small pilot study, using made between matched populations of patients with case-control methodology. The pilot study investithe selected adverse effect (cases) and those without gated whether selected SNPs within ABCB1 and any adverse effect (controls).
CYP2C9, which might influence the pharmacokinet-ics of the COX-2 inhibitors by (a) altering the pas-cases or controls. However, the number of case sage of drugs through biological membranes and/or patients (15 of the 37 approached [41%]) and con-(b) altering the metabolism of the drugs, were asso-trol patients (24 of the 91 approached [26%]) who ciated with an increase in the susceptibility of pa-consented to participate and were genotyped was tients to psychiatric and visual disturbance. In the greatly in excess of those who agreed to participate case and control samples genotyped (table I) , sever-in our earlier genotyping study where DNA was al variants were found that could potentially lead to extracted from peripheral blood. [13] A lower percentaltered substrate transport by P-gp or metabolism by age of controls than cases agreed to participate. This CYP2C9. may have been because of the lack of direct interest due to not having experienced an adverse reaction, The results from this study suggest that genetic in spite of being supplied with the information that variability in P-gp or CYP2C9 may not contribute to knowledge of their genotypes might assist in the the rare psychiatric or visual disturbances associated choice of other types of medications that could be with celecoxib and rofecoxib. However, as the samneeded in the future. ple size in this pilot study was small, there is a possibility of type II error that would be minimised Because of time constraints, follow-up of pain a large population study. Furthermore, we only tients who had not returned consent forms was not examined one of the many SNPs that have been carried out. However, as several patient consent described in ABCB1 and we cannot rule out the forms were received following the closing date for possibility that genetic variability in P-gp does im-the study, it is likely that telephone follow-up would pact on these COX-2 inhibitor-related ADRs. Two have improved the return rate. It is also possible that recent studies [26, 27] investigating sequence diversity methods other than telephone follow-up could inin ABCB1 have identified over 30 different SNP crease the return rate. In future investigations we haplotypes of this gene, of which 14 were found to intend to approach patients by asking the prescribers include 3435C>T. [27] Results from these haplotyp-to co-sign and to forward the letters, describing the ing studies strongly suggest that although screening intention of the study and inviting participation, to for 3435C>T is a good starting point, to fully assess their patients. This was an Ethics Committee rethe potential impact of P-gp genetic variability on quirement for a future study and it may also improve drug response it is necessary to screen patients for patient acceptance of the study objectives. Although haplotypes rather than individual SNPs.
we informed patients that doctors' fees would be paid by the IMMP, it may be possible that the offer Despite an apparent lack of association between of a financial reward to patients for participation selected P-gp and CYP2C9 variants and COX-2 would increase enrolment. However, in some couninhibitor-induced psychiatric or visual disturbances tries, including New Zealand, the ethics of offering a in this study, we have demonstrated that a less financial incentive to participate would be subject to invasive method for obtaining DNA than using peintense scrutiny. ripheral blood samples is acceptable and that genetic studies can be linked with pharmacovigilance data Linking pharmacogenetics and pharmacovigito provide information on genetic variation that may lance in epidemiological studies that use non-invaalter susceptibility to ADRs.
sive sampling methods has the potential to clarify Because of health and other reasons, including the population risk of particular variant genes in some recent deaths, we were requested by the GPs increasing susceptibility to particular ADRs. PEM not to approach several of the patients selected as databases, as in the DSRU in England and the IMMP in New Zealand, have cohorts drawn from absorption, distribution and elimination of many the general population who have been prescribed the drugs, [31, 32] and this may contribute to serious ADRs monitored drug(s), with information on outcomes of or interactions. [33, 34] In addition, P-gp expression in therapy and other patient details. Patients with and endothelial cells of the CNS prevents the penetration without particular adverse events can be identified of several drugs across the blood-brain barriand their genotypes compared. We concur with the er. [12, 35, 36] The ABCB1 gene is highly polymorphic opinion expressed by Tucker [28] that "the challenge and many variant forms of P-gp show significantly now is to assemble large, prospective, multidiscipli-reduced transporter function. One of the most comnary, multicentre projects". Case-control studies de-mon of these variant forms has a mutation signed to assess the risk of selected variant SNPs (3435C>T) in exon 26 of the ABCB1 gene. Subjects and haplotypes in predisposing towards adverse out-with the 3435T allele produce P-gp with altered comes from drug therapy in the 'real world' of substrate transport function compared with subjects clinical practice will contribute to the evidence ob-with the 3435C allele. In some studies the 3435T tained from future large-scale prospective studies.
allele has been associated with increased P-gp function, whereas in other studies this variant appears to 4. Future Directions encode a protein with impaired activity. [37] [38] [39] It is possible that these discrepancies in relation to Examples of genes that are known to influence 3435T reflect differences in haplotypes. Our pilot drug responses are provided in several reports. [28] study sought to determine whether this known We have selected examples below where research ABCB1 mutation is associated with increased suson the population risk of genetic variability in influceptibility to developing visual or psychiatric effects encing therapeutic effect and the susceptibility to in patients receiving celecoxib or rofecoxib. ADRs is underway or is needed urgently. Further P-gp is known to transport many anticancer detail is provided on genetic variability in P-gp and drugs [12, 16] and several other clinically important CYP2C9: examples that may impact on pharmadrugs including some statins (atorvastatin, lovastacokinetics. Two further examples where genetic vatin), [40] digoxin, [41, 42] some calcium channel antagoriation may affect pharmacodynamics are also disnists (diltiazem, verapamil), [43] the angiotensin II cussed.
receptor antagonist losartan, [44, 45] erythromycin, [40] 4.1 Pharmacokinetic Variation fexofenadine, [46] nortriptyline [47] and phenytoin. [33] These examples have been selected because, in some cases, studies (referenced after drug names)
Variations Affecting P-Glycoprotein Function
have associated P-gp genetic polymorphisms with P-gp is a transmembrane protein efflux pump adverse effects or potentially important effects on encoded by the ABCB1 gene (formerly known as pharmacokinetics. Therefore, they are potentially MDR1). As discussed earlier, P-gp functions to eximportant candidate drugs for population studies trude many drugs and other 'foreign' lipophilic aimed at assessing the association of variant P-gp compounds from the cells back into the extracellular and ADRs. More complete lists of drugs that are space, thereby preventing substrates from accumuknown substrates for P-gp may be obtained from lating in critical organs such as the brain. [29, 30] P-gp Schwab et al. [16] and Marzolini et al. [12] It is imporhas been isolated in endothelial cells of the gut, tant that the risks of genetic variation in the function kidney, liver and other organs. [12] Because of this, it has an important role in determining the extent of of P-gp on adverse outcomes of drugs, including adverse interactions between drugs, are determined system ADRs associated with celecoxib, compared in large populations.
with patients identified as carriers for CYP2C9 alleles other than CYP2C9*3 (Layton D, DSRU, per-
Variations Affecting Drugs Metabolised by sonal communication).
Cytochrome P450 (CYP) 2C9 and Other Polymorphic CYP Enzymes
Pharmacodynamic Variation
The CYP enzymes are a group of haemoproteins responsible for catalysing the phase I metabolism of
Genetic Variation in β-Adrenergic Receptors:
almost all drugs. [48] Over recent years emphasis has Association with Adverse Outcomes from been placed on the clinical implications of genetic β-Adrenoceptor Agonist Therapy variability in CYP2D6 because this enzyme is in-β-Adrenoceptor agonists are the most commonly volved in the metabolism of a wide range of current-used medication for rapid bronchodilation during ly prescribed drugs. [49] acute asthma episodes. However, serious adverse outcomes may occur with the use of β-agonists, CYP2C9 is one of the four known members of the including long-acting β-agonists. [58] [59] [60] These may human 2C family and, although it has received less involve the respiratory, cardiovascular or neuromusattention than CYP2D6, it is one of the most abuncular systems. dant CYPs found in the human liver. [50] [51] [52] [53] [54] [55] CYP2C9 accounts for about 20% of the total liver CYP conOf particular note are adverse respiratory outtent and is responsible for the metabolic clearance of comes that occur following the use of long-acting β-about 10% of all drugs currently in use. [20, 54] agonists, such as salmeterol and formoterol. [61] When these drugs are used regularly, some patients Several polymorphisms have been observed in find that they do not get their usual relief from shortthe CYP2C9 enzyme. [54, 56] Of these polymorphisms, acting β-agonist therapy. In this respect, there is two alleles referred to as CYP2C9*2 and CYP2C9*3 conclusive evidence that subsensitivity of lead to the reduced function of the enzyme. Muta-β 2-adrenergic receptors develops when long-acting tions that alter amino acids in the substrate recogni-β-agonists are used regularly. [62] A number of SNPs tion sites of CYP2C9 proteins (such as the *3 allele) in the β2-adrenoceptor (ADRB2) gene have been can markedly reduce the metabolic ability of the described. [63] To date, the most important of these enzyme [54, 56] and have clinically significant effects appear to confer variation in both the acute reon the pharmacokinetics of some drugs. [57] Although sponses to β2-receptor stimulation and in their proour small pilot study did not confirm that visual and pensity for desensitisation and downregulation. [63] [64] [65] psychiatric adverse reactions are associated with reduced CYP2C9 metabolism, it remains possible Lima et al. [66] reported that bronchodilator rethat this is an important risk for susceptibility to sponses, resulting from acute administration of adverse gastrointestinal events, including gastroin-salbutamol, are enhanced in patients with an argitestinal bleeding and ulceration that may follow nine substitution in position 16 of the ADRB2 gene celecoxib and other NSAID use. The risk that genet-(Gly>Arg polymorphism). This raised the possibiliic variants of CYP enzymes pose for NSAID and ty that the continuous use of short-acting β2-agonists other drug use needs to be assessed using case-or of long-acting β-agonists such as salmeterol or control studies in large populations. In the UK, the formoterol may result in downregulation of the DSRU is commencing a study to investigate wheth-β2-receptors. Israel et al. [8] and Taylor et al. [58] have er patients identified as being hetero-or homozy-shown a consistent relationship between the presgous for CYP2C9*3 have a higher risk of alimentary ence of the Arg-16 allele and deterioration in lung function during regular treatment with the short-Alteration in the rate of cardiac cell membrane repoacting β-agonist salbutamol. In the study by Taylor larisation is reflected by a prolongation of the QT et al., [58] the frequency of exacerbations of asthma interval, a common cause of serious dysrhythmias was increased in patients who were homozygous for including torsade de pointes.
[69] The two most comthe Arg-16 allele. In addition, the benefits of regular mon types of inherited long QT syndromes (LQT1, salmeterol treatment were much less in homozygous LQT2) are due to variant genes that affect the funcArg-16 patients than in the other genotypes. There-tion of cardiac cell membrane potassium channels: fore, there is strong evidence to support the hypothe-KCNQ1 (formerly known as KVLQT1) and KCNH2 sis that adverse outcomes may be determined by (formerly known as HERG). A third, less common, ADRB2 genotype. Research is planned in the IMMP type of long QT syndrome (LQT3) is due to variants to determine the risk for the development of adverse of a gene (SCN5A) that codes for sodium channels outcomes from specific genetic variations following (INa). [70] treatment with long-acting β-agonists.
K + currents that pass through specialised K + As in the case of ABCB1, although individual channels are the predominant outward currents in SNPs in ADRB2 may influence drug response, heart muscle involved in membrane repolarisation. haplotypes may be more clinically relevant. The most predominant K + current responsible for Haplotype analysis of the ADRB2 gene and its pro-ventricular repolarisation is known as I K, of which moter region takes into account the possibility that there are two distinct components: IKr and IKs (rapid combinations of SNPs may confer particular pheno-and slow). Several mutations exist in the genes that typic effects.
[67] In New Zealand, the most common code for the potassium channel proteins, KCNQ1 functionally relevant haplotypes are 4/4, 2/2, 4/6, 2/ and KCNH2. Individuals carrying these mutant 4 and 2/6 [68] and the frequency of specific genes have reduced function in transporting K + from haplotypes is sufficiently common that they can be the cells and are therefore susceptible to long QT identified in modestly sized groups of subjects. interval and, when taking drugs that also potentially Therefore, genetic analyses in populations using inhibit IK currents, are at a high risk of QT prolongashort-and long-acting β-agonists should provide tion and serious arrhythmias. [71] Lists of such drugs evidence relating adverse outcomes in patients tak-may be found in the literature [70, 72] and Internet sites ing inhaled long-acting β-agonists to combination (e.g. http://www.torsades.org), which are updated as haplotypes, as well as to the important SNPs. In new examples come to light. They include well spite of advances in asthma management, asthma known examples, such as terfenadine, cisapride, anmorbidity and mortality remain high. In view of this tipsychotic medications and also drugs such as sibuand because of concerns regarding serious adverse tramine and dexfenfluramine, [73] where investigaoutcomes following long-acting β-agonist use, [60] tions in animals have provided an indication of the determination in populations of specific genetic va-potential to prolong QT interval. riation in β-receptors and the risks following β-More research is needed to identify further drugs agonist use is needed urgently. associated with this serious problem and to measure the risk of a long corrected QT interval (QTc) with Risk Evaluation] study). This research will systemAcknowledgements atically document and follow up incident cases of A generous grant from the New Zealand Pharmacy Edudrug-induced ventricular arrhythmia in England and cation and Research Foundation has enabled us to undertake compare them with matched controls. In addition, the experimental work described in this article. We are also grateful to Janelle Ashton for invaluable assistance with this blood samples from case and control patients will be study and to Deborah Layton and Andrew Boshier for further analysed for mutations and polymorphisms of the information on pharmacogenetic studies initiated in the Drug potassium and sodium channel genes implicated in Safety Research Unit. Dr Kennedy is a Senior Research the long QT and similar syndromes. [74] Results from Furthermore, the studies will help to establish in which circumstances genotyping should be per- 
